PT880362E - COMPOSITIONS COMPOSING A CYCLOXYGENASE INHIBITOR TYPE 2 AND A LEUCOTYRENE RECEIVER ANTAGONIST B4 - Google Patents
COMPOSITIONS COMPOSING A CYCLOXYGENASE INHIBITOR TYPE 2 AND A LEUCOTYRENE RECEIVER ANTAGONIST B4Info
- Publication number
- PT880362E PT880362E PT97905663T PT97905663T PT880362E PT 880362 E PT880362 E PT 880362E PT 97905663 T PT97905663 T PT 97905663T PT 97905663 T PT97905663 T PT 97905663T PT 880362 E PT880362 E PT 880362E
- Authority
- PT
- Portugal
- Prior art keywords
- alkyl
- arylamino
- aralkylaminoalkyl
- arylaminosulfonyl
- arylaminoalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
Use of a leukotriene B 4 receptor antagonist and a cyclooxygenase-2 inhibitor,
wherein the cyclooxygenase-2 inhibitor is selected from compounds of Formula I:
wherein A is pyrazolyl;
wherein R 1 is at least one substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R 1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
wherein R 2 is selected from alkyl and amino; and
wherein R 3 is a radical selected from halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclooxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl;
or a pharmaceutically-acceptable salt thereof, for preparing a medicament to suppress immune, acute or delayed-type hypersensitivity response in a subject.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60058096A | 1996-02-13 | 1996-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT880362E true PT880362E (en) | 2005-10-31 |
Family
ID=24404169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT97905663T PT880362E (en) | 1996-02-13 | 1997-02-11 | COMPOSITIONS COMPOSING A CYCLOXYGENASE INHIBITOR TYPE 2 AND A LEUCOTYRENE RECEIVER ANTAGONIST B4 |
Country Status (10)
Country | Link |
---|---|
US (3) | US6172096B1 (en) |
EP (2) | EP1640003A2 (en) |
JP (1) | JP2000505445A (en) |
AT (1) | ATE296114T1 (en) |
AU (1) | AU2250097A (en) |
CA (1) | CA2246356A1 (en) |
DE (1) | DE69733338T2 (en) |
ES (1) | ES2243978T3 (en) |
PT (1) | PT880362E (en) |
WO (1) | WO1997029775A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0828718A1 (en) | 1995-06-02 | 1998-03-18 | G.D. SEARLE & CO. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
ATE296114T1 (en) * | 1996-02-13 | 2005-06-15 | Searle & Co | PREPARATIONS CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUCOTRIEN B4 RECEPTOR ANTAGONIST |
ES2169351T3 (en) | 1996-02-13 | 2002-07-01 | Searle & Co | COMBINATIONS THAT HAVE IMMUNOSUPPRESSOR EFFECTS, CONTAINING CYCLOXYGENASA-2 AND 5-LIPOXYGENASE INHIBITORS. |
CA2246336A1 (en) * | 1996-02-13 | 1997-08-21 | G.D. Searle & Co. | Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor |
CA2313049A1 (en) * | 1997-12-17 | 1999-06-24 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
US7041694B1 (en) * | 1997-12-17 | 2006-05-09 | Cornell Research Foundation, Inc. | Cyclooxygenase-2 inhibition |
US6767890B1 (en) * | 1998-11-18 | 2004-07-27 | Coastside Bio Resources | Peptides having anti-cancer and anti-inflammatory activity |
US20030017148A1 (en) * | 2000-05-11 | 2003-01-23 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
AR038957A1 (en) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | COMBINATION THERAPY FOR CANCER TREATMENT |
BR0309754A (en) * | 2002-05-02 | 2007-03-13 | Univ Washington | methods and compositions for treating t-cell mediated autoimmune / inflammatory disorders and diseases in subjects having a glucocorticoid regulatory deficiency |
US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
US7354574B2 (en) * | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
RS20050390A (en) * | 2002-11-26 | 2008-04-04 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg., | Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor |
US20040242676A1 (en) * | 2003-05-30 | 2004-12-02 | Alessi Thomas R. | Method of mitigating the adverse effects of IL-2 |
US7083802B2 (en) * | 2003-07-31 | 2006-08-01 | Advanced Ocular Systems Limited | Treatment of ocular disease |
JP2007505932A (en) | 2003-09-18 | 2007-03-15 | マクサイト, インコーポレイテッド | Transscleral delivery |
US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
US7083803B2 (en) * | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
US20050181018A1 (en) * | 2003-09-19 | 2005-08-18 | Peyman Gholam A. | Ocular drug delivery |
JP4793692B2 (en) * | 2004-04-26 | 2011-10-12 | 小野薬品工業株式会社 | Novel BLT2-mediated diseases, BLT2-binding agents and compounds |
EP1790338A4 (en) * | 2004-09-13 | 2007-12-12 | Santen Pharmaceutical Co Ltd | Therapeutic agent for keratoconjunctiva disorder |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
BRPI0608152A2 (en) | 2005-02-09 | 2009-11-10 | Macusight Inc | eye care formulations |
EP1879881A2 (en) * | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
WO2007011880A2 (en) | 2005-07-18 | 2007-01-25 | Minu, L.L.C. | Enhanced ocular neuroprotection/neurostimulation |
US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
PL2001466T3 (en) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Low-dose rapamycin for the treatment of vascular permeability-related diseases |
WO2008008549A2 (en) * | 2006-07-14 | 2008-01-17 | Boston Medical Center Corporation | Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia |
US20090017140A1 (en) * | 2007-07-09 | 2009-01-15 | Peter Koepke | Maytenus abenfolia extract and methods of extracting and using such extract |
US20090035395A1 (en) * | 2007-08-01 | 2009-02-05 | Peter Koepke | Spondias mombin l. extract and methods of extracting and using such extract |
US7879369B2 (en) * | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59196839A (en) | 1983-04-21 | 1984-11-08 | Sankyo Co Ltd | Phenylacetic acid derivative |
US4923891A (en) | 1987-09-24 | 1990-05-08 | G. D. Searle & Co. | Leukotriene LTD4 and LTB4 antagonists |
US4970234A (en) | 1987-12-08 | 1990-11-13 | G. D. Searle & Co. | Furyl, phenylene, and thienyl leukotriene B4 analogues |
US4889935A (en) | 1987-12-18 | 1989-12-26 | American Home Products Corporation | Aminoguanidine derivatives |
US4871771A (en) | 1988-02-04 | 1989-10-03 | Smithkline Beckman Corporation | Leukotriene antagonists |
US5384318A (en) * | 1989-06-22 | 1995-01-24 | Pfizer Inc. | Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases |
US5256686A (en) | 1989-06-27 | 1993-10-26 | Ono Pharmaceutical Co., Ltd. | Phenylalkan(en)oic acid |
US5212198A (en) | 1990-05-10 | 1993-05-18 | G. D. Searle & Co. | Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof |
US5124350A (en) | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
US5121198A (en) * | 1990-06-28 | 1992-06-09 | Eastman Kodak Company | Method of setting the contrast of a color video picture in a computer controlled photographic film analyzing system |
FR2665159B1 (en) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
JPH0439864U (en) * | 1990-07-30 | 1992-04-03 | ||
US5232948A (en) | 1990-09-10 | 1993-08-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
US5210208A (en) | 1990-09-24 | 1993-05-11 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity |
IE913655A1 (en) | 1990-11-06 | 1992-05-22 | Zeneca Ltd | Synergistic agents |
US5246965A (en) * | 1991-06-11 | 1993-09-21 | Ciba-Geigy | Arylethers, their manufacture and methods of treatment |
US5272178A (en) | 1991-11-18 | 1993-12-21 | G. D. Searle & Co. | Compounds of cyclic phenolic thioethers which are useful in stimulating and inhibiting superoxide generation |
DE4141746A1 (en) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-METHYL-SUBSTITUTED VITAMIN D DERIVATIVES |
GB9215921D0 (en) | 1992-07-27 | 1992-09-09 | Wellcome Found | Anti-inflammatory compounds |
DE4228201A1 (en) | 1992-08-25 | 1994-03-03 | Schering Ag | New leukotriene B¶4¶ antagonists, processes for their preparation and their use as medicines |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
CA2293952A1 (en) | 1993-01-15 | 1994-07-21 | David B. Reitz | Preparation of esters and analogs thereof |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
US5380740A (en) | 1993-04-28 | 1995-01-10 | G. D. Searle & Co. | Anti-inflammatory compounds, compositions and method of use thereof |
AU6718494A (en) | 1993-05-13 | 1994-12-12 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
US5380738A (en) | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5412151A (en) | 1993-10-22 | 1995-05-02 | Eastman Chemical Company | Thermosetting coating compositions |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
WO1995015316A1 (en) * | 1993-11-30 | 1995-06-08 | G. D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5434178A (en) | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
KR100297091B1 (en) | 1993-12-09 | 2001-11-05 | 고래마츠 교지 | Chrome-free brick |
US5393790A (en) | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
AU6269496A (en) * | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
ATE296114T1 (en) * | 1996-02-13 | 2005-06-15 | Searle & Co | PREPARATIONS CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUCOTRIEN B4 RECEPTOR ANTAGONIST |
-
1997
- 1997-02-11 AT AT97905663T patent/ATE296114T1/en not_active IP Right Cessation
- 1997-02-11 PT PT97905663T patent/PT880362E/en unknown
- 1997-02-11 JP JP9529359A patent/JP2000505445A/en not_active Ceased
- 1997-02-11 DE DE69733338T patent/DE69733338T2/en not_active Expired - Fee Related
- 1997-02-11 EP EP05003990A patent/EP1640003A2/en not_active Withdrawn
- 1997-02-11 WO PCT/US1997/001422 patent/WO1997029775A1/en active IP Right Grant
- 1997-02-11 AU AU22500/97A patent/AU2250097A/en not_active Abandoned
- 1997-02-11 CA CA002246356A patent/CA2246356A1/en not_active Abandoned
- 1997-02-11 ES ES97905663T patent/ES2243978T3/en not_active Expired - Lifetime
- 1997-02-11 EP EP97905663A patent/EP0880362B1/en not_active Expired - Lifetime
-
1998
- 1998-05-11 US US09/075,633 patent/US6172096B1/en not_active Expired - Fee Related
-
2000
- 2000-09-12 US US09/659,299 patent/US6617345B1/en not_active Expired - Fee Related
-
2003
- 2003-07-10 US US10/617,222 patent/US7141599B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6172096B1 (en) | 2001-01-09 |
US20040106668A1 (en) | 2004-06-03 |
WO1997029775A1 (en) | 1997-08-21 |
ATE296114T1 (en) | 2005-06-15 |
US7141599B2 (en) | 2006-11-28 |
DE69733338T2 (en) | 2006-03-16 |
DE69733338D1 (en) | 2005-06-30 |
US6617345B1 (en) | 2003-09-09 |
EP1640003A2 (en) | 2006-03-29 |
CA2246356A1 (en) | 1997-08-21 |
ES2243978T3 (en) | 2005-12-01 |
JP2000505445A (en) | 2000-05-09 |
EP0880362A1 (en) | 1998-12-02 |
AU2250097A (en) | 1997-09-02 |
EP0880362B1 (en) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT880362E (en) | COMPOSITIONS COMPOSING A CYCLOXYGENASE INHIBITOR TYPE 2 AND A LEUCOTYRENE RECEIVER ANTAGONIST B4 | |
CA2249009A1 (en) | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors | |
NZ509755A (en) | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | |
Blum | The missing reversioner: reflections on the status of Judea and Samaria | |
RU99110192A (en) | METHOD OF USE OF CYCLOXYGENASE-2 INHIBITORS FOR TREATMENT AND PREVENTION OF NEOPLASION | |
US20080153894A1 (en) | Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis | |
US20040214753A1 (en) | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | |
EP1397145B1 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, or tic disorders | |
WO2004082588A2 (en) | Dispersible formulation of an anti-inflammatory agent | |
MXPA05001167A (en) | Gelatin capsule exhibiting reduced cross-linking. | |
JP2005538994A5 (en) | ||
AR020306A1 (en) | THERAPEUTIC COMPOSITION AND ITS USE AS AN INHIBITOR OF CICLOOXIGENASA-2 IN THE PREVENTION OF CARDIOVASCULAR ALTERATIONS. | |
US20040105884A1 (en) | Pharmaceutical dosage form comprising a sulfite compound | |
US20040105883A1 (en) | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | |
JP2001521889A5 (en) | ||
WO2005009472A2 (en) | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders | |
ZA200307575B (en) | Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2inhibitor), a solvent, a fatty acid and an organic amine. | |
Lenta | The purposes of torture | |
Tancredi | In search of a fair balance between the inviolability of borders, self-determination and secession in international law | |
Morales | Special Treatment in the Execution of the Penalty of Deprivation of Liberty for Juveniles in the Field of International Human Rights Law and Dogmatic | |
Yule | GEOGRAPHY AND MASSACRE. | |
Spohr | Hot topic: Stand, bow, sit: disrespectful court behaviour |